fda tirzepatide shortage resolved oct 2 2024 Eli Lilly's is off the FDA's drug list: Here's what it means FDA Affirms Decision on Tirzepatide

Semaglutide is a GLP-1 medication that reduces appetite and food cravings and slows stomach emptying, helping you eat less and lose weight steadily

Purity & third-party testing Every batch of Retatrutide 40mg is independently analysed by Janoshik Analytical, with a Certificate of Analysis confirming identity and 99% purity available on request

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

The elimination of glucose via urinary excretion can have other secondary consequences, both good and bad

Do I Have to Stay On It